STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer
Mené sur 409 patients atteints d'un adénocarcinome rectal (28 % de femmes), cet essai randomisé international de phase II/III évalue l'intérêt, du point de vue de la préservation de l'organe après 30 mois, d'une radiochimiothérapie de longue durée par rapport à une radiothérapie de courte durée
The adoption of total mesorectal excision (TME) has significantly reduced the risk of locoregional recurrence in patients with rectal cancer. However, this reduction comes at the cost of substantial treatment-related morbidity, including permanent stoma formation and long-term impairment of bowel, urinary, and sexual function that adversely impact quality of life (QOL) and functionality.1 As such, management has evolved toward risk-adapted, patient-centred strategies, including selective organ preservation that is oncologically safe and associated with better QOL.
The Lancet Oncology , commentaire, 2026